{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:46:30Z","timestamp":1792237590673,"version":"4.4.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-46504-y","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T08:29:04Z","timestamp":1775204944000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of thalidomide in \u03b2-thalassaemia: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"16","author":[{"given":"Nirmani","family":"Yasara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajith","family":"Thilakarathne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. D. C.","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuja","family":"Premawardhena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachith","family":"Mettananda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"46504_CR1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bcmd.2017.06.001","volume":"70","author":"SL Thein","year":"2018","unstructured":"Thein, S. L. Molecular basis of \u03b2 thalassemia and potential therapeutic targets. Blood Cells Mol. Dis. 70, 54\u201365 (2018).","journal-title":"Blood Cells Mol. Dis."},{"key":"46504_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102619","author":"Y Tuo","year":"2024","unstructured":"Tuo, Y. et al. Global, regional, and national burden of thalassemia, 1990\u20132021: A systematic analysis for the global burden of disease study 2021. eClinicalMedicine https:\/\/doi.org\/10.1016\/j.eclinm.2024.102619 (2024).","journal-title":"eClinicalMedicine"},{"key":"46504_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2023.148022","volume":"896","author":"E Rao","year":"2024","unstructured":"Rao, E., Kumar Chandraker, S., Misha Singh, M. & Kumar, R. Global distribution of \u03b2-thalassemia mutations: An update. Gene 896, 148022 (2024).","journal-title":"Gene"},{"key":"46504_CR4","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2017.018","volume":"9","author":"V De Sanctis","year":"2017","unstructured":"De Sanctis, V. et al. \u03b2-thalassemia distribution in the old world: An ancient disease seen from a historical standpoint. Mediterr. J. Hematol. Infect. Dis. 9, e2017018 (2017).","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"46504_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4038\/sljch.v47i2.8484","volume":"47","author":"S Mettananda","year":"2018","unstructured":"Mettananda, S. Management of thalassaemia. Sri Lanka J. Child Health 47, 159 (2018).","journal-title":"Sri Lanka J. Child Health"},{"key":"46504_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13023-021-01757-w","volume":"16","author":"N Yasara","year":"2021","unstructured":"Yasara, N., Premawardhena, A. & Mettananda, S. A comprehensive review of hydroxyurea for \u03b2-haemoglobinopathies: The role revisited during COVID-19 pandemic. Orphanet J. Rare Dis. 16, 114 (2021).","journal-title":"Orphanet J. Rare Dis."},{"key":"46504_CR7","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3390\/hematolrep16040064","volume":"16","author":"J Malay","year":"2024","unstructured":"Malay, J. et al. Gene therapy: A revolutionary step in treating thalassemia. Hematol. Rep. 16, 656\u2013668 (2024).","journal-title":"Hematol. Rep."},{"key":"46504_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48204-2","volume":"9","author":"S Mettananda","year":"2019","unstructured":"Mettananda, S. et al. Synergistic silencing of \u03b1-globin and induction of \u03b3-globin by histone deacetylase inhibitor, vorinostat as a potential therapy for \u03b2-thalassaemia. Sci. Rep. 9, 11649 (2019).","journal-title":"Sci. Rep."},{"key":"46504_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176404","volume":"968","author":"D-L Cai","year":"2024","unstructured":"Cai, D.-L. et al. Ginsenoside Rg1 promotes fetal hemoglobin production in vitro: A potential therapeutic avenue for \u03b2-thalassemia. Eur. J. Pharmacol. 968, 176404 (2024).","journal-title":"Eur. J. Pharmacol."},{"key":"46504_CR10","doi-asserted-by":"publisher","first-page":"S197","DOI":"10.3109\/03630260903351882","volume":"33","author":"A El-Beshlawy","year":"2009","unstructured":"El-Beshlawy, A., Hamdy, M. & El Ghamrawy, M. Fetal globin induction in \u03b2-thalassemia. Hemoglobin 33, S197\u2013S203 (2009).","journal-title":"Hemoglobin"},{"key":"46504_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1182\/blood-2017-06-790121","volume":"131","author":"AT Taher","year":"2018","unstructured":"Taher, A. T. et al. Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: Results from a phase 2a study. Blood 131, 263\u2013265 (2018).","journal-title":"Blood"},{"key":"46504_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/toxsci\/kfr088","volume":"122","author":"JH Kim","year":"2011","unstructured":"Kim, J. H. & Scialli, A. R. Thalidomide: The tragedy of birth defects and the effective treatment of disease. Toxicol. Sci. 122, 1\u20136 (2011).","journal-title":"Toxicol. Sci."},{"key":"46504_CR13","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S0149-2918(03)80085-1","volume":"25","author":"SJ Matthews","year":"2003","unstructured":"Matthews, S. J. & McCoy, C. Thalidomide: A review of approved and investigational uses. Clin. Ther. 25, 342\u2013395 (2003).","journal-title":"Clin. Ther."},{"key":"46504_CR14","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.bcmd.2008.03.001","volume":"41","author":"LB Aguilar-Lopez","year":"2008","unstructured":"Aguilar-Lopez, L. B., Delgado-Lamas, J. L., Rubio-Jurado, B., Javier Perea, F. & Ibarra, B. Thalidomide therapy in a patient with thalassemia major. Blood Cells Mol. Dis. 41, 136\u2013137 (2008).","journal-title":"Blood Cells Mol. Dis."},{"key":"46504_CR15","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.clinthera.2025.01.008","volume":"47","author":"H Yang","year":"2025","unstructured":"Yang, H. et al. Effects of Thalidomide on metabolism and lifespan of red blood cell in patients with \u03b2-Thalassemia Major: A post hoc analysis of a randomized controlled trial. Clin. Ther. 47, 252\u2013260 (2025).","journal-title":"Clin. Ther."},{"key":"46504_CR16","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s12288-020-01263-2","volume":"36","author":"A Nag","year":"2020","unstructured":"Nag, A. et al. Thalidomide in patients with transfusion-dependent E-Beta Thalassemia refractory to Hydroxyurea: A single-center experience. Indian J. Hematol. Blood Transfus. 36, 399\u2013402 (2020).","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"46504_CR17","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s12288-022-01620-3","volume":"39","author":"U Bhattacharjee","year":"2023","unstructured":"Bhattacharjee, U. et al. A phase 2 randomized controlled trial of single-agent hydroxyurea versus thalidomide among adult transfusion dependent \u03b2 thalassemia patients. Indian J. Hematol. Blood Transfus. 39, 266\u2013275 (2023).","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"46504_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000040328","volume":"103","author":"W Ju","year":"2024","unstructured":"Ju, W. et al. Efficacy and safety of thalidomide in patients with \u03b2-thalassemia intermedia and major. Medicine (Baltimore) 103, e40328 (2024).","journal-title":"Medicine (Baltimore)"},{"key":"46504_CR19","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1001\/jamasurg.2021.0522","volume":"156","author":"BS Brooke","year":"2021","unstructured":"Brooke, B. S., Schwartz, T. A. & Pawlik, T. M. MOOSE reporting guidelines for meta-analyses of observational studies. JAMA Surg. 156, 787\u2013788 (2021).","journal-title":"JAMA Surg."},{"key":"46504_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 372, n71 (2021).","journal-title":"BMJ"},{"key":"46504_CR21","unstructured":"Guidelines for the Management of Transfusion-Dependent \u03b2-Thalassaemia. (Thalassaemia International Federation, Nicosia, Cyprus, 2025)."},{"key":"46504_CR22","unstructured":"Guidelines for the Management of Non-Transfusion-Dependent \u03b2-Thalassaemia. (Thalassaemia International Federation, Nicosia, Cyprus, 2023)."},{"key":"46504_CR23","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. (The Cochrane Collaboration and John Wiley & Sons Ltd., 2008)."},{"key":"46504_CR24","unstructured":"Study Quality Assessment Tools | NHLBI, NIH. https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools."},{"key":"46504_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins, J. P. T., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. BMJ 327, 557\u2013560 (2003).","journal-title":"BMJ"},{"key":"46504_CR26","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/biom.12817","volume":"74","author":"L Lin","year":"2018","unstructured":"Lin, L. & Chu, H. Quantifying publication bias in meta-analysis. Biometrics 74, 785\u2013794 (2018).","journal-title":"Biometrics"},{"key":"46504_CR27","doi-asserted-by":"publisher","first-page":"6162","DOI":"10.1182\/bloodadvances.2022007031","volume":"6","author":"SH Ansari","year":"2022","unstructured":"Ansari, S. H. et al. Evaluation of the combination therapy of hydroxyurea and thalidomide in \u03b2-thalassemia. Blood Adv. 6, 6162\u20136168 (2022).","journal-title":"Blood Adv."},{"key":"46504_CR28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/03630269.2024.2386076","volume":"48","author":"S Bhattacharjee","year":"2024","unstructured":"Bhattacharjee, S., Ghosh, S., Shaw, J., Bhattacharjee, S. & Bhattacharyya, M. Thalidomide and hydroxyurea in transfusion-dependent thalassemia: Efficacy, safety profile and impact on quality of life. Hemoglobin 48, 161\u2013168 (2024).","journal-title":"Hemoglobin"},{"key":"46504_CR29","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.2147\/IJGM.S462991","volume":"17","author":"W Zhu","year":"2024","unstructured":"Zhu, W. et al. Long-term follow-up of patients undergoing thalidomide therapy for transfusion-dependent \u03b2-thalassaemia: A single-center experience. Int. J. Gen. Med. 17, 1729\u20131738 (2024).","journal-title":"Int. J. Gen. Med."},{"key":"46504_CR30","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41392-021-00811-0","volume":"6","author":"J-M Chen","year":"2021","unstructured":"Chen, J.-M. et al. Safety and efficacy of thalidomide in patients with transfusion-dependent \u03b2-thalassemia: A randomized clinical trial. Signal Transduct. Target. Ther. 6, 405 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"46504_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-40849-4","volume":"13","author":"Z Ali","year":"2023","unstructured":"Ali, Z. et al. Long-term clinical efficacy and safety of thalidomide in patients with transfusion-dependent \u03b2-thalassemia: Results from Thal-Thalido study. Sci. Rep. 13, 13592 (2023).","journal-title":"Sci. Rep."},{"key":"46504_CR32","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s13312-021-2254-y","volume":"58","author":"J Chandra","year":"2021","unstructured":"Chandra, J. et al. Efficacy and safety of thalidomide in patients with transfusion-dependent thalassemia. Indian Pediatr. 58, 611\u2013616 (2021).","journal-title":"Indian Pediatr."},{"key":"46504_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2021.102544","volume":"88","author":"M Jain","year":"2021","unstructured":"Jain, M. et al. Comparison of efficacy and safety of thalidomide vs hydroxyurea in patients with Hb E-\u03b2 thalassemia - a pilot study from a tertiary care Centre of India. Blood Cells. Mol. Dis. 88, 102544 (2021).","journal-title":"Blood Cells. Mol. Dis."},{"key":"46504_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30391","volume":"70","author":"X Jian","year":"2023","unstructured":"Jian, X. et al. Long-term efficacy and safety of thalidomide treatment in children with \u03b2-thalassemia major. Pediatr. Blood Cancer 70, e30391 (2023).","journal-title":"Pediatr. Blood Cancer"},{"key":"46504_CR35","doi-asserted-by":"crossref","unstructured":"Li, X. et al. Efficacy of thalidomide treatment in children with transfusion dependent \u03b2-thalassemia: A retrospective clinical study. Front. Pharmacol. 12, (2021).","DOI":"10.3389\/fphar.2021.722502"},{"key":"46504_CR36","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1007\/s00277-018-3395-5","volume":"97","author":"Q Ren","year":"2018","unstructured":"Ren, Q. et al. Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia. Ann. Hematol. 97, 1933\u20131939 (2018).","journal-title":"Ann. Hematol."},{"key":"46504_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2020.102442","volume":"84","author":"K Yang","year":"2020","unstructured":"Yang, K. et al. The association of HBG2, BCL11A, and HBS1L-MYB polymorphisms to thalidomide response in Chinese \u03b2-thalassemia patients. Blood Cells Mol. Dis. 84, 102442 (2020).","journal-title":"Blood Cells Mol. Dis."},{"key":"46504_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-024-01963-y","volume":"17","author":"W Yang","year":"2024","unstructured":"Yang, W. et al. Clinical efficacy of thalidomide for various genotypes of beta thalassemia. BMC Med. Genomics 17, 191 (2024).","journal-title":"BMC Med. Genomics"},{"key":"46504_CR39","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s12288-019-01231-5","volume":"36","author":"AK Yassin","year":"2020","unstructured":"Yassin, A. K. Promising response to thalidomide in symptomatic \u03b2-thalassemia. Indian J. Hematol. Blood Transfus. 36, 337\u2013341 (2020).","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"46504_CR40","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.20038","volume":"13","author":"WM Bawazir","year":"2025","unstructured":"Bawazir, W. M. et al. Genetic modifiers of response to thalidomide in transfusion-dependent beta-thalassemia patients: A whole-exome sequence analysis. PeerJ 13, e20038 (2025).","journal-title":"PeerJ"},{"key":"46504_CR41","doi-asserted-by":"publisher","unstructured":"Dolai, T. K. et al. Safety and effectiveness of thalidomide in transfusion-dependent and non-transfusion-dependent thalassaemia children in eastern India. Indian J. Hematol. Blood Transfus. https:\/\/doi.org\/10.1007\/s12288-025-02205-6 (2025).","DOI":"10.1007\/s12288-025-02205-6"},{"key":"46504_CR42","doi-asserted-by":"publisher","first-page":"2561219","DOI":"10.1080\/07853890.2025.2561219","volume":"57","author":"X Li","year":"2025","unstructured":"Li, X. et al. Clinical patterns of thalidomide in the treatment of transfusion-dependent \u03b2-thalassaemia in children: A prospective single-arm study in China. Ann. Med. 57, 2561219 (2025).","journal-title":"Ann. Med."},{"key":"46504_CR43","doi-asserted-by":"crossref","unstructured":"Mishra, V. et al. Evaluating health-related quality of life in thalassemia: low-dose thalidomide vs. standard care\u2014insights from a comparative study. Hemoglobin 49, 78\u201384 (2025).","DOI":"10.1080\/03630269.2025.2473526"},{"key":"46504_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2025.102936","volume":"113\u2013114","author":"IU Rahman","year":"2025","unstructured":"Rahman, I. U. et al. Thalidomide confers therapeutic benefit in beta thalassemia patients by enhancing hemoglobin and hematopoietic gene expression: A non-randomized clinical trial. Blood Cells. Mol. Dis. 113\u2013114, 102936 (2025).","journal-title":"Blood Cells. Mol. Dis."},{"key":"46504_CR45","doi-asserted-by":"publisher","unstructured":"Singha, J., Jacoby, A. P., Bhattacharya, S. & Das, S. S. Pilot study on the efficacy and safety of thalidomide in transfusion-dependent and non-transfusion-dependent thalassemia: A prospective, non-randomized interventional study. Indian J. Hematol. Blood Transfus. https:\/\/doi.org\/10.1007\/s12288-025-02162-0 (2025).","DOI":"10.1007\/s12288-025-02162-0"},{"key":"46504_CR46","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1365-2141.2010.08397.x","volume":"151","author":"P Rigano","year":"2010","unstructured":"Rigano, P. et al. Desensitization to hydroxycarbamide following long-term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients. Br. J. Haematol. 151, 509\u2013515 (2010).","journal-title":"Br. J. Haematol."},{"key":"46504_CR47","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1038\/s41598-022-06774-8","volume":"12","author":"N Yasara","year":"2022","unstructured":"Yasara, N. et al. A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent \u03b2-thalassaemia. Sci. Rep. 12, 2752 (2022).","journal-title":"Sci. Rep."},{"key":"46504_CR48","unstructured":"Jalali Far, M. A. et al. Thalidomide is more efficient than sodium butyrate in enhancing GATA-1 and EKLF gene expression in erythroid progenitors derived from HSCs with \u03b2-globin gene mutation. Int. J. Hematol.-Oncol. Stem Cell Res. 10, 37\u201341 (2016)."},{"key":"46504_CR49","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1182\/blood-2007-01-065201","volume":"110","author":"W Aerbajinai","year":"2007","unstructured":"Aerbajinai, W., Zhu, J., Gao, Z., Chin, K. & Rodgers, G. P. Thalidomide induces \u03b3-globin gene expression through increased reactive oxygen species\u2013mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis. Blood 110, 2864\u20132871 (2007).","journal-title":"Blood"},{"key":"46504_CR50","doi-asserted-by":"publisher","first-page":"e2024001","DOI":"10.4084\/MJHID.2024.001","volume":"16","author":"K Yang","year":"2024","unstructured":"Yang, K. & Xiao, J. Thalidomide ameliorates erythropoiesis and iron homeostasis in transfusion dependent \u03b2-thalassemia. Mediterr. J. Hematol. Infect. Dis. 16, e2024001\u2013e2024001 (2024).","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"46504_CR51","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/ejh.12955","volume":"99","author":"J Chen","year":"2017","unstructured":"Chen, J. et al. Thalidomide induces haematologic responses in patients with \u03b2-thalassaemia. Eur. J. Haematol. 99, 437\u2013441 (2017).","journal-title":"Eur. J. Haematol."},{"key":"46504_CR52","first-page":"201","volume":"14","author":"Z Ali","year":"2022","unstructured":"Ali, Z., Ismail, M., Khan, M. T. M. & Rehman, I. U. Safety and efficacy of thalidomide in transfusion-dependent \u03b2-thalassaemia: A systematic review and meta-analysis. KHYBER Med. Univ. J. 14, 201\u2013206 (2022).","journal-title":"KHYBER Med. Univ. J."},{"key":"46504_CR53","doi-asserted-by":"crossref","unstructured":"Lu, Y., Wei, Z., Yang, G., Lai, Y. & Liu, R. Investigating the efficacy and safety of thalidomide for treating patients with \u00df-thalassemia: A meta-analysis. Front. Pharmacol. 12, (2022).","DOI":"10.3389\/fphar.2021.814302"},{"key":"46504_CR54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-190608","volume":"142","author":"S Kakkar","year":"2023","unstructured":"Kakkar, S. et al. Efficacy of low dose Vs standard dose of thalidomide in patients with transfusion-dependent thalassemia (TDT): A non-inferiority trial. Blood 142, 2473 (2023).","journal-title":"Blood"},{"key":"46504_CR55","doi-asserted-by":"publisher","first-page":"e2020021","DOI":"10.4084\/mjhid.2020.021","volume":"12","author":"K Yang","year":"2020","unstructured":"Yang, K. et al. Thalidomide for patients with thalassemia intermedia: A retrospective multicenter clinical study. Mediterr. J. Hematol. Infect. Dis. 12, e2020021\u2013e2020021 (2020).","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"46504_CR56","doi-asserted-by":"publisher","first-page":"E141","DOI":"10.1002\/ajh.24030","volume":"90","author":"C Fozza","year":"2015","unstructured":"Fozza, C. et al. Dramatic erythroid response to low-dose thalidomide in two patients with transfusion independent thalassemia and severe post-transfusional alloimmune hemolysis. Am. J. Hematol. 90, E141\u2013E141 (2015).","journal-title":"Am. J. Hematol."},{"key":"46504_CR57","doi-asserted-by":"publisher","first-page":"102","DOI":"10.30574\/wjbphs.2024.18.2.0250","volume":"18","author":"SU Vishe","year":"2024","unstructured":"Vishe, S. U., Lokhande, R. P., Wagh, S. A., Pathan, S. D. & Pathan, S. R. An in-depth review of thalidomide\u2019s basic moieties. World J. Biol. Pharm. Health Sci. 18, 102\u2013109 (2024).","journal-title":"World J. Biol. Pharm. Health Sci."},{"key":"46504_CR58","unstructured":"Rahaman, J. et al. Seroprevalence and co-infection of hepatitis B and hepatitis C among patients in a tertiary care hospital in eastern India."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46504-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46504-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46504-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T01:03:00Z","timestamp":1779411780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46504-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["46504"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-46504-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"6 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"15933"}}